Rahul Garg, MD
Cardiovascular Disease · Rome, GANPI 1326109851
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 254 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by Johnson & Johnson at 41.2% of the total. Reporting peaked in 2021 at $952 and has fallen 64.1% since, to $342 in 2025.
Across 254 payments — averaging $21.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- AstraZeneca$489
- Novartis$315
- Cordis US CORP.$237
- Pfizer$227
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$206
- plus $2K from 24 others
Across 1 payment — averaging $8802.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$9K
What the payments were for
- Travel & lodging$781%
- Food & beverage$5,28198%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 123 | $2,212 |
| AstraZeneca | 11 | $489 |
| Novartis | 16 | $315 |
| Cordis US CORP. | 13 | $237 |
| Pfizer | 12 | $227 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 14 | $206 |
| Lexicon Pharmaceuticals, Inc. | 5 | $184 |
| Boston Scientific | 6 | $143 |
| Actelion Pharmaceuticals US, Inc. | 2 | $138 |
| Akebia Therapeutics Inc | 1 | $125 |
| Calliditas Therapeutics US Inc. | 1 | $124 |
| Novo Nordisk | 5 | $100 |
| Merck | 4 | $86 |
| Chiesi USA, Inc. | 6 | $86 |
| Medtronic(2 entities) | 5 | $84 |
| E.r. Squibb & Sons, L.L.C. | 6 | $82 |
| Livanova USA, Inc. | 1 | $78 |
| Amgen | 5 | $74 |
| Abbott | 1 | $63 |
| Osprey Medical Inc | 4 | $54 |
| W. L. Gore & Associates, Inc. | 1 | $42 |
| Esperion Therapeutics, Inc. | 2 | $42 |
| Fresenius USA Marketing, Inc. | 2 | $35 |
| Boehringer Ingelheim | 1 | $30 |
| Shockwave Medical, Inc | 2 | $27 |
| ANI Pharmaceuticals, Inc. | 1 | $24 |
| Cvrx, Inc. | 1 | $23 |
| Nuwellis, Inc. | 1 | $19 |
| Bayer | 1 | $16 |
| Bardy Diagnostics, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,373 in reported general payments places this provider in the 70th percentile of 640 cardiovascular disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 814 | $875,861 |
| XareltoRivaroxaban | 385 | $414,886 |
| EntrestoSacubitril/Valsartan | 145 | $173,034 |
| Repatha SureclickEvolocumab | 111 | $87,241 |
| BrilintaTicagrelor | 53 | $41,269 |
| FarxigaDapagliflozin Propanediol | 37 | $37,268 |
| JardianceEmpagliflozin | 42 | $34,014 |
| Ranolazine ErRanolazine | 122 | $11,061 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 736 | $9,113 |
| ClopidogrelClopidogrel Bisulfate | 574 | $7,232 |
| Atorvastatin Calcium | 722 | $6,979 |
| Nitroglycerin | 727 | $6,915 |
| Metoprolol Tartrate | 1,320 | $6,554 |
| Metoprolol Succinate | 368 | $6,312 |
| Praluent PenAlirocumab | 11 | $6,311 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $227 | $875,861814 claims |
| Johnson & JohnsonXarelto | $2,212 | $414,886385 claims |
| NovartisEntresto | $315 | $173,034145 claims |
| AstraZenecaBrilinta, Farxiga | $489 | $78,53890 claims |
| Boehringer IngelheimJardiance, Pradaxa | $30 | $36,34153 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 640 cardiovascular disease providers in Georgia.
Other cardiovascular disease in Rome
- Charles JacksonRome$17K
- Narendra SinghJohns Creek$1.6M
- Hunter ChampionColumbus$1.5M
- Nicolas ChronosEatonton$912K
- Jaime BurkleGainesville$628K
- Joseph MillerAtlanta$573K
- Kashyap ChoksiThomasville$263K
- Utpal PandyaAtlanta$221K
- Randolph MartinAtlanta$177K
- Hiren ShahColumbus$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.